BD Fiscal Q3 2026 Earnings: Revenue Grows as GAAP Operating Profit Falls

BD (NYSE: BDX) reported fiscal third-quarter 2026 revenue of $4.983 billion, up 5.4% from $4.726 billion, while diluted EPS from continuing operations rose 4.5% to $1.64 from $1.57. Adjusted diluted EPS increased 4.9% to $3.23, but GAAP operating income fell 10.3% as operating costs grew faster than revenue. The quarter ended June 30, 2026, and prior-period results were recast for continuing operations following the February 2026 spin-off of the former Biosciences and Diagnostic Solutions business.

Core earnings data

Revenue increased 4.4% on a foreign currency-neutral basis, compared with 5.4% as reported. Net income from continuing operations was essentially unchanged, but a lower diluted share count helped GAAP EPS increase.

Total net income, which includes discontinued operations, declined because discontinued operations produced a $74 million loss in the latest quarter versus $123 million of income a year earlier.

Gross profit and margin are approximate calculations based on reported revenue and cost of products sold.

Business and segment performance

All four continuing operating segments generated reported and currency-neutral growth. Interventional delivered the largest dollar increase and the fastest currency-neutral segment growth, while BioPharma Systems posted the highest reported growth rate.

Within Connected Care, Advanced Patient Monitoring grew 10.9% as reported and 11.2% on a currency-neutral basis, making it the fastest-growing disclosed business unit. Specimen Management increased 8.7% as reported and 7.0% currency-neutral, while Peripheral Intervention and Surgery also recorded mid-to-high-single-digit growth.

The geographic results showed a more pronounced difference. U.S. revenue rose 6.9% to $3.081 billion, while international revenue increased 3.2% as reported but only 0.6% currency-neutral. International Medication Delivery Solutions declined 1.8% as reported and 4.7% currency-neutral, partly offsetting stronger international results in businesses such as Advanced Patient Monitoring and Surgery.

Higher operating costs offset revenue growth

Total operating costs and expenses rose 8.4%, faster than the 5.4% increase in revenue. Cost of products sold increased 7.1%, contributing to the lower gross margin, while selling and administrative expense rose 8.4% and research and development expense increased 12.0%. Other operating expense also climbed to $44 million from $7 million.

As a result, quarterly operating costs increased by about $334 million while revenue increased by about $257 million, pushing GAAP operating income down 10.3%. Management said adjusted operating margin exceeded its internal expectations, but the release did not provide the quarterly adjusted margin figure.

The gap between GAAP and adjusted EPS also remained substantial. The largest adjustment was $1.32 per share for purchase accounting, with additional adjustments for integration, restructuring, separation-related, product remediation and legal items. Meanwhile, diluted shares outstanding declined by about 4.2% to 275.2 million, allowing EPS from continuing operations to rise even though continuing net income was nearly flat.

Cash flow and balance sheet

The reported cash flow figures cover the first nine months of fiscal 2026 rather than the third quarter alone. Cash provided by continuing operating activities increased 33.3% to $2.104 billion, while free cash flow rose 44.6% to $1.728 billion. Capital expenditures were broadly stable at $376 million versus $383 million, and the outflow associated with changes in operating assets, liabilities and other items narrowed to $319 million from $883 million.

Cash and equivalents stood at $708 million on June 30, up from $567 million at the end of fiscal 2025. Inventory increased to $3.316 billion from $3.149 billion. Current and long-term debt totaled about $16.8 billion, down from approximately $19.2 billion at the fiscal year-end, although current debt obligations rose to $3.297 billion as long-term debt declined.

Financing activity during the nine-month period included a $3.857 billion distribution from the spin-off entity, $2.696 billion of debt repayments, $2.250 billion of share repurchases and $875 million of dividends.

Fiscal 2026 guidance

As of August 6, BD raised the lower end of its adjusted diluted EPS range while leaving the upper end unchanged, increasing the midpoint by about $0.05. Revenue growth ranges were maintained, but the company now expects reported growth toward the high end of its range.

The adjusted EPS outlook represents growth of 6.1% to 6.9% from fiscal 2025 adjusted EPS of $11.90.

Management perspective

Chairman, CEO and President Tom Polen described the quarter as BD’s first full reporting period as “New BD” following the separation. Management attributed operating momentum to key growth platforms, continued product innovation and progress under BD Excellence, while maintaining its focus on margin expansion and disciplined capital allocation.

Recent insider transactions

The supplied insider dataset reports 59,884 shares purchased across seven transactions and 6,366 shares sold across 10 transactions during the last six months, resulting in net purchases of 53,518 shares. Total insider holdings were listed at 1.16 million shares, with a 4.80% net purchase ratio; the recent transaction list also includes stock awards and a derivative-security conversion, which are distinct from open-market purchases.

Risks investors should monitor

• Operating-cost growth: Costs rose faster than revenue during the quarter, reducing both gross and operating margins. Continued expense growth at this pace could limit the earnings benefit from higher sales.
• Slower underlying international growth: International revenue increased only 0.6% currency-neutral, compared with 6.9% growth in the United States. Weakness in selected international product lines could widen that gap.
• GAAP and adjusted earnings divergence: Purchase accounting and other adjustments created a significant difference between GAAP EPS of $1.64 and adjusted EPS of $3.23. Restructuring, separation and product-related charges may continue to affect reported profitability.
• Tariff and supply-chain uncertainty: BD said its outlook depends on assumptions involving tariffs, potential tariff refunds, trade restrictions and input costs. Changes in those factors could affect margins and the full-year guidance range.

Summary

BD’s fiscal third quarter combined broad-based segment growth and improved year-to-date cash generation with weaker GAAP operating profitability. The main issue is whether revenue momentum—particularly in Interventional and Advanced Patient Monitoring—can outpace operating costs and slower currency-neutral international growth, allowing BD to deliver its higher adjusted EPS guidance while narrowing the gap between reported and adjusted results.